(Q34019043)

30 July 2017

1 reference

title

Current status of cardiac surgery in the abciximab-treated patient (English)

1 reference

30 July 2017

0 references

1 reference

S C Silvestry

1

1 reference

30 July 2017

P K Smith

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

The Annals of Thoracic Surgery

30 July 2017

published in

1 reference

30 July 2017

volume

70

1 reference

30 July 2017

issue

2 Suppl

1 reference

30 July 2017

page(s)

S12-9

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Preventing coronary restenosis and complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Usefulness of abciximab for treatment of early coronary artery stent thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Abciximab and excessive bleeding in patients undergoing emergency cardiac operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

The incidence and natural history of pericardial effusion after cardiac surgery--an echocardiographic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Pericardial effusion after cardiac surgery: incidence, relation to the type of surgery, antithrombotic therapy, and early coronary bypass graft patency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Determinants of red cell, platelet, plasma, and cryoprecipitate transfusions during coronary artery bypass graft surgery: the Collaborative Hospital Transfusion Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

A model for predicting transfusion after coronary artery bypass grafting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Intraoperative autotransfusion reduces blood loss after cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Aortocoronary bypass following unsuccessful PTCA: experience in 100 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

1988: Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Updated in 1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Reopro removal during cardiopulmonary bypass using a hemoconcentrator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

The platelet in cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2800%2901602-7

10.1016/S0003-4975(00)01602-7

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference